BioLife Solutions(US:BLFS) Prnewswire·2024-05-29 12:04Core Insights - BioLife Solutions, Inc. has introduced the CryoCase, a new primary packaging solution for cell and gene therapy (CGT) that aims to replace traditional cryopreservation bags with a more durable and efficient container [2][3]. Product Features - The CryoCase is designed for closed-system fill and retrieval of larger fluid volumes (less than 75mL) and features a transparent design for better compliance with inspection standards [3]. - It is manufactured under strict controls to minimize particulates, which are a growing concern in drug product manufacturing [3][4]. - Early testing indicates that the CryoCase maintains comparable cell viability and recovery compared to existing storage methods, while also demonstrating high resistance to leaks and fractures [3]. Market Positioning - The introduction of the CryoCase is positioned as a solution to reduce risks and costs in CGT manufacturing, aligning with the industry's need for improved primary containers [4]. - The product is compatible with various downstream processing systems, enhancing its integration into existing workflows [4]. Availability and Demonstration - The CryoCase is expected to be available for CGT developers in August and is currently being demonstrated at the ISCT event in Vancouver, Canada [2]. - Samples of the CryoCase are available for testing, indicating the company's proactive approach to market engagement [4]. Company Overview - BioLife Solutions is recognized as a leading supplier of bioproduction tools and services for the CGT and broader biopharma markets, focusing on maintaining the health and function of biologic materials throughout their lifecycle [5].